FDA Approves Foundayo, New Weight Loss Pill From Eli Lilly

The U.S. Food and Drug Administration (FDA) has approved Foundayo, a new oral medication developed by Eli Lilly, for the treatment of obesity and weight-related health issues. This approval, granted on April 1, 2026, marks a notable milestone as Foundayo is the second oral GLP-1 (glucagon-like peptide-1) medication to hit the market, following the approval of Novo Nordisk’s Wegovy in December 2025.

Foundayo, known scientifically as orforglipron, is a once-daily pill that can be taken at any time of day without restrictions on food or water intake. This flexibility is a major selling point, especially when compared to Wegovy, which must be taken on an empty stomach. According to Eli Lilly, the drug aims to provide a more accessible option for individuals reluctant to use injectable treatments, which have traditionally been the standard for GLP-1 therapies.

In clinical trials, patients taking the highest dose of Foundayo lost an average of 27.3 pounds, or about 12.4% of their body weight, over a 72-week period. In comparison, those on a placebo lost only 2.2 pounds (0.9%). These results were part of the ATTAIN-1 clinical trial, which involved over 3,000 participants from various countries, including the U.S., Brazil, and Japan.

"People living with obesity need treatment options that meet them where they are, and for many, a once-daily pill can offer greater flexibility in how they approach their treatment," said Dr. Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. Eli Lilly’s CEO, David Ricks, emphasized the importance of making such medications accessible, stating, "Fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications."

Foundayo will be available through LillyDirect, with prescriptions accepted immediately and shipping set to begin on April 6, 2026. It will also become available through U.S. retail pharmacies and telehealth providers shortly thereafter. The pricing structure is aimed at making the medication affordable: eligible patients with commercial insurance may pay as little as $25 per month with the Foundayo savings card, whereas self-pay patients will start at $149 per month for the lowest dose, with higher doses potentially costing up to $349 per month.

Dr. Jody Dushay, an endocrinologist and obesity expert at Harvard Medical School, expressed cautious optimism about the new medication. She noted that many patients switching from injectable GLP-1 drugs to oral options often find the weight loss less substantial. "The jury is still out in terms of what people are really going to achieve with these pills," she commented. Yet, the convenience of taking a pill may appeal to those who have struggled with injections.

In addition to its weight loss benefits, Foundayo has shown potential in reducing cardiovascular risk factors, such as waist circumference and cholesterol levels. The drug mimics the effects of a natural hormone that regulates appetite and feelings of fullness, making it a promising option for long-term weight management.

Side effects reported during clinical trials were similar to those seen with other GLP-1 medications, including gastrointestinal issues such as nausea, constipation, and diarrhea. More serious risks include the potential for thyroid tumors, prompting warnings for patients to monitor for symptoms such as neck lumps or hoarseness.

As the market for weight loss medications continues to expand, the introduction of Foundayo adds to the competition. Analysts predict that the global market for anti-obesity drugs could reach $105 billion by 2030. The quick FDA approval process for Foundayo, taking just 50 days—the fastest for a new drug type since 2002—highlights the urgency and importance of addressing obesity as a public health crisis.

Both Eli Lilly and Novo Nordisk are investing heavily in the development of GLP-1 medications, with Lilly also working on another GLP-1 drug, retatrutide, which has shown promise in trials for greater weight loss. The rivalry between these companies is expected to intensify as they compete for market share in the rapidly growing obesity treatment sector.

In a world where obesity affects over 100 million people in the U.S. alone, the need for effective and accessible treatment options is more pressing than ever. Foundayo’s approval provides a new tool for weight management and aims to reduce the stigma associated with obesity and improve the lives of those struggling with weight-related health issues.

As the rollout of Foundayo begins, it will be important to monitor its uptake among patients and the extent to which insurance companies choose to cover the medication. With the potential for Medicare coverage to start as early as summer 2026, many individuals may soon find themselves with more options for managing their weight effectively.

As David Ricks noted, "This is a population health problem and it needs a population health solution. We want to impact human health, and we have the opportunity to do that with this pill." The initiative to make Foundayo widely available could represent a turning point in the fight against obesity, making a tangible difference in the lives of many.